ROGAINE Rx-TO-OTC SWITCH STUMBLES ON ISSUE OF BALDNESS MISDIAGNOSIS: ADVISORY COMMITTEE SPLITS HAIRS ABOUT "MEANINGFUL" EFFICACY; ACTUAL-USE STUDY URGED
Executive Summary
Upjohn's attempt to have Rogaine switched from Rx to OTC status stumbled on the issue of potential consumer misdiagnosis of the masons behind balding, resulting in a 10-4 vote against approval of the switch of topical minoxidil 2% at a July 27 meeting of the Nonprescription Drugs Advisory Committee.